Wells Fargo initiated coverage on Bruker with a new price target
$BRKR
Biotechnology: Laboratory Analytical Instruments
Industrials
Wells Fargo initiated coverage of Bruker with a rating of Overweight and set a new price target of $78.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $72.00 | Buy | Guggenheim |
| 12/10/2024 | $66.00 | Neutral | UBS |
| 12/5/2024 | $60.00 | Sell → Neutral | Goldman |
| 10/15/2024 | $75.00 | Overweight | Barclays |
| 9/30/2024 | Outperform → Peer Perform | Wolfe Research | |
| 8/28/2024 | $78.00 | Overweight | Wells Fargo |
| 6/3/2024 | $85.00 | Buy | Jefferies |
| 2/14/2024 | $60.00 → $90.00 | Neutral → Overweight | JP Morgan |
Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00
UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00
Goldman upgraded Bruker from Sell to Neutral and set a new price target of $60.00
Bruker Corporation (NASDAQ:BRKR) today announces the launch of the new X4 POSEIDON™, a high-performance 3D X-ray microscope (XRM) using micro-Computed Tomography (microCT). This innovative benchtop XRM system offers advanced capabilities comparable to larger, floor-standing systems to make high-resolution 3D X-ray microscopy accessible for demanding XRM applications in industrial applications and scientific research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227078535/en/X4 POSEIDON – a versatile, high-performance benchtop XRM system (Photo: Business Wire) The X4 POSEIDON features a high-end X-ray source that improves 3D
A. Preview of timsTOF Ultra 2 system with novel Athena Ion Processor (AIP): - Improves protein group identification in single-cell proteomics (SCP) by 15%-20%, and peptide identifications in SCP by 20%-25% -Advances immunopeptidomics with 15%-20% more immunopeptide identifications B. Launch of DeutEx™ software for hydrogen-deuterium exchange (HDX-MS) analysis C. OmniScape™ 2025b: a breakthrough in top-down protein sequencing software D. Advances in ProteoScape™ and Glycoproteomics software capabilities E. Advances in TwinScape™ for cloud-based, AI-enabled proteomics quality monitoring At the 21st Annual US HUPO Conference, Bruker Corporation (NASDAQ:BRKR) announces significant
Advancements to include CosMx® Whole Transcriptome Panel; enhanced technology engine to power CellScape™ for spatial proteomics; expansion to 1000-plex protein assay on GeoMx® DSP; and launch of PaintScape™, a revolutionary platform enabling direct visualization of the 3D genome Bruker Corporation (NASDAQ:BRKR) announced today that it will unveil significant advancements in spatial biology at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting. Bruker Spatial Biology will announce the following four innovations that underscore Bruker's leading commitment to advancing spatial biology with pioneering, best-in-class platforms: This press release features multimedia. View
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with
Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic
ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral disease ELITechGroup has its R&D, manufacturing and commercial focus on Europe and the Americas Bruker to acquire ELITechGroup revenues of ~Euro 150 million p.a. with >80% consumables revenue Bruker Corporation (NASDAQ:BRKR) announced today that
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on March 28, 2025 to stockholders of record as of March 17, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microsc
Bruker Corporation (NASDAQ:BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before market opening on Thursday, February 13, 2025. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q4 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-43
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on December 16, 2024 to stockholders of record as of December 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and
4 - BRUKER CORP (0001109354) (Issuer)
3 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
10-K - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)